Module 3 · NEET Biology

Human Reproduction & Reproductive Health

Updated 17 Nov 2026 · 7,131 words · 6 sections
Updated 21 Nov 2026
Reproductive systems, gametogenesis, the menstrual cycle, and reproductive health.
Reproduction · Gametogenesis · Health
🎯 Take Mock Test

Learning Objectives

  • Understand the fundamental concepts of Human Reproduction & Reproductive Health
  • Apply key formulas and techniques to solve problems
  • Practice with exam-level questions to build speed and accuracy

1. Male Reproductive System

1.1 Testes and Accessory Glands

The male reproductive system is organised around the paired testes, which reside in the scrotum where a temperature approximately two to three degrees Celsius lower than core body temperature is maintained; this thermal gradient is essential for the progression of spermatogenesis. Each testis is encapsulated by the tunica albuginea and partitioned into lobules that contain the seminiferous tubules, the site of sperm production, while the interstitial Leydig cells synthesize testosterone under the influence of luteinising hormone. The epididymis, a tightly coiled tube on the posterior surface of each testis, receives immature spermatozoa and provides the microenvironment for their maturation and acquisition of motility. Accessory glands — the seminal vesicles, prostate gland, and bulbourethral glands — secrete the bulk of seminal fluid, contributing fructose for energy, prostaglandins for uterine contractility, and alkaline buffers that neutralise vaginal acidity.

1.2 Spermatogenesis

Spermatogenesis is a continuous, highly ordered process that transforms diploid spermatogonia into haploid spermatozoa through mitotic proliferation, meiotic reduction, and spermiogenesis. Spermatogonial stem cells near the basal lamina undergo mitosis to maintain the stem cell pool and to generate primary spermatocytes, which then enter meiosis I to form secondary spermatocytes and subsequently meiosis II to produce four haploid spermatids. During spermiogenesis, each spermatid remodels its nucleus, acquires an acrosome derived from the Golgi apparatus, develops a flagellum from the centriole, and sheds excess cytoplasm as residual bodies that are phagocytosed by Sertoli cells. The entire cycle from spermatogonia to mature spermatozoa spans roughly 64 days in humans, and the seminiferous epithelium exhibits a cyclic arrangement of cellular associations known as stages, ensuring a constant output of sperm.

1.3 Hormonal Regulation of Male Reproduction

The hypothalamic‑pituitary‑gonadal axis governs testicular function through pulsatile release of gonadotropin‑releasing hormone (GnRH) from the hypothalamus, which stimulates the anterior pituitary to secrete follicle‑stimulating hormone (FSH) and luteinising hormone (LH). LH acts on Leydig cells to promote testosterone synthesis, while FSH binds to receptors on Sertoli cells, stimulating the production of androgen‑binding protein and inhibin. Testosterone exerts negative feedback on both the hypothalamus and pituitary, reducing GnRH and LH secretion, whereas inhibin selectively suppresses FSH. This feedback loop maintains relatively stable hormone concentrations, and any disruption — such as a Leydig cell tumour or pituitary adenoma — can lead to altered spermatogenesis and secondary sexual characteristics.

1.4 Transport and Maturation of Sperm

After spermiation, spermatozoa are transported from the seminiferous tubules into the rete testis, then through the efferent ductules into the epididymis where they gain progressive motility and fertilising capacity over a period of 10 to 14 days. During ejaculation, peristaltic contractions of the vas deferens propel sperm into the ejaculatory ducts, where they mix with seminal vesicle fluid, prostatic secretions, and bulbourethral mucus to form semen. The alkaline pH of semen protects sperm from the acidic vaginal environment, and the fructose supplied by the seminal vesicles fuels mitochondrial ATP production required for flagellar movement. Successful deposition of semen in the female reproductive tract initiates the final capacitation steps that render sperm competent for zona pellucida binding.

2. Female Reproductive System

2.1 Ovaries and Accessory Structures

The female gonads are the paired ovaries, almond‑shaped organs situated in the ovarian fossa of the pelvic cavity, each attached to the uterus by the ovarian ligament and to the pelvic wall by the suspensory ligament that carries the ovarian vessels. The outer cortex of the ovary contains ovarian follicles at various stages of development, while the inner medulla houses blood vessels, lymphatics, and connective tissue. The fallopian tubes, or uterine tubes, extend from the uterine horns toward the ovaries; their fimbriated infundibulum captures the ovulated oocyte and provides the site of fertilisation in the ampulla. The uterus is a thick‑walled muscular organ composed of the fundus, body, and cervix; its inner lining, the endometrium, undergoes cyclic remodeling under hormonal control. The vagina serves as the copulatory organ and birth canal, its mucosa maintained by glycogen‑dependent lactobacilli that create an acidic environment protective against pathogens.

2.2 Oogenesis

Oogenesis begins in fetal life when oogonia proliferate by mitosis and enter meiosis I, arresting at prophase I as primary oocytes within primordial follicles; this arrest persists until puberty. Each menstrual cycle, a cohort of follicles is recruited under the influence of FSH, but typically only one dominant follicle completes meiosis I just before ovulation, producing a secondary oocyte and a first polar body. The secondary oocyte immediately begins meiosis II and arrests at metaphase II; completion of this division occurs only if fertilisation takes place, yielding a mature ovum and a second polar body. The unequal cytokinesis ensures that the ovum retains most of the cytoplasm, organelles, and maternal mRNAs essential for early embryonic development, while the polar bodies degenerate. The finite pool of primordial follicles determines the reproductive lifespan, and the progressive decline in follicle number underlies the onset of menopause.

2.3 Hormonal Regulation of the Female Cycle

The menstrual cycle is orchestrated by the same hypothalamic‑pituitary axis that regulates male reproduction, but the pattern of gonadotropin secretion is cyclical rather than tonic. In the early follicular phase, rising FSH stimulates granulosa cell proliferation and aromatase activity, converting theca‑cell‑derived androgens into estradiol. Increasing estradiol exerts negative feedback on FSH while sensitising the pituitary to GnRH, culminating in a massive LH surge that triggers ovulation and luteinisation of the residual follicular cells into the corpus luteum. The corpus luteum secretes progesterone and estradiol, which together prepare the endometrium for implantation and suppress further gonadotropin release through negative feedback. If pregnancy does not occur, the corpus luteum regresses after about 14 days, hormone levels fall, and the functional layer of the endometrium is shed as menstruation, initiating a new cycle.

2.4 The Uterus, Fallopian Tubes and Vagina

The uterus responds to ovarian steroids by undergoing distinct proliferative and secretory phases; estrogen drives endometrial glandular and stromal proliferation, while progesterone induces glandular secretion, stromal edema, and spiral artery coiling, creating a receptive environment for a blastocyst. The fallopian tubes are lined with ciliated and secretory epithelial cells; ciliary beating and smooth muscle peristalsis transport the oocyte or zygote toward the uterus, and the tubal fluid provides nutrients and a suitable ionic milieu. The vagina’s stratified squamous epithelium thickens under estrogen influence, and its glycogen content supports lactobacilli that produce lactic acid, maintaining a pH around 4.5 that inhibits many pathogenic microbes. During sexual arousal, vaginal transudate provides lubrication, and the cervix produces mucus whose viscosity changes cyclically — thin and alkaline at ovulation to facilitate sperm passage, thick and acidic in the luteal phase to form a barrier.

Example Question
A 28‑year‑old woman has a regular 28‑day menstrual cycle. On day 14 a surge of luteinising hormone triggers ovulation. Which hormone is primarily responsible for the maintenance of the corpus luteum after ovulation, and what is its source?
The hormone is luteinising hormone (LH) itself, which continues to be secreted by the anterior pituitary at lower amplitude after the surge; LH binds to receptors on the corpus luteum, stimulating progesterone production that maintains the uterine lining.
Exam‑Day Insight
When a question asks for the hormone that sustains the corpus luteum, remember that LH is the physiological luteotrophic hormone in the non‑pregnant cycle; hCG only takes over after implantation.

3. Gametogenesis: Comparative Overview

3.1 Spermatogenesis versus Oogenesis

Although both processes rely on meiosis to halve the chromosome number, spermatogenesis and oogenesis differ profoundly in timing, cellular output, and cytoplasmic allocation. In males, spermatogonia divide continuously from puberty onward, producing millions of sperm each day, whereas in females the entire complement of primary oocytes is established before birth and only a few hundred will ever resume meiosis. The symmetric cytokinesis of spermatogenesis yields four equally sized spermatids, each capable of becoming a functional spermatozoon, while the highly asymmetric divisions of oogenesis generate one large ovum and three tiny polar bodies that are discarded. Hormonal control also diverges: FSH and testosterone drive spermatogenesis, whereas FSH and LH coordinate follicular development and ovulation. These differences reflect the distinct reproductive strategies of the sexes — massive, continuous gamete production in males versus a limited, cyclical release of a single, nutrient‑rich gamete in females.

Comparison of spermatogenesis and oogenesis
FeatureSpermatogenesisOogenesis
SiteSeminiferous tubules of testesOvarian cortex
OnsetPuberty, continuous throughout lifeFetal life, arrested until puberty
Meiotic outcomeFour functional spermatozoa per primary spermatocyteOne functional ovum and three polar bodies per primary oocyte
Cytoplasmic distributionEqual cytokinesisHighly unequal cytokinesis
Hormonal controlFSH and testosteroneFSH and LH

3.2 Meiotic Divisions and Chromosome Number

Both spermatogenesis and oogenesis involve two successive meiotic divisions, but the checkpoints and timing differ. In spermatocytes, meiosis I separates homologous chromosomes, and meiosis II separates sister chromatids, producing four haploid nuclei each containing 23 chromosomes. In oocytes, meiosis I is completed only at ovulation, and meiosis II arrests at metaphase II until fertilisation; this arrest is maintained by high levels of maturation‑promoting factor (MPF) and cytostatic factor (CSF). Errors in chromosome segregation during either division can lead to aneuploidy; nondisjunction in oogenesis is a major cause of trisomies such as Down syndrome, whereas spermatogenic errors more frequently result in sex chromosome aneuploidies like Klinefelter syndrome. The prolonged prophase I arrest in oocytes, lasting decades, increases the risk of cohesion fatigue and spindle defects, explaining the maternal age effect on chromosomal abnormalities.

3.3 Timing and Output Differences

The temporal dynamics of gametogenesis have direct clinical implications. Spermatogenesis takes approximately 64 days from spermatogonial stem cell to mature spermatozoon, and the process is continuous, meaning that any transient insult — such as fever, toxin exposure, or hormonal disruption — will affect sperm output only after a lag of two to three months. In contrast, the ovarian follicular wave that culminates in ovulation spans roughly two weeks, and the dominant follicle is selected during the early follicular phase; thus, acute stressors can influence the current cycle immediately. The sheer number of sperm produced — on the order of 100 million per ejaculate — provides a statistical buffer against defects, whereas the single ovum per cycle means that any defect in that oocyte has a proportionally larger impact on fertility.

3.4 Clinical Significance of Gametogenic Errors

Defects in spermatogenesis manifest as oligozoospermia, asthenozoospermia, or teratozoospermia, and can be caused by genetic mutations (e.g., AZF deletions on the Y chromosome), varicocele, endocrine disorders, or environmental toxins. In females, premature ovarian insufficiency, polycystic ovary syndrome, and age‑related decline in oocyte quality are common causes of infertility. Assisted reproductive technologies such as intracytoplasmic sperm injection (ICSI) can bypass many spermatogenic defects by injecting a single sperm directly into the oocyte, while in vitro maturation (IVM) of oocytes offers a strategy for women with impaired follicular development. Understanding the molecular checkpoints of meiosis — such as the role of cohesin complexes, the spindle assembly checkpoint, and the synaptonemal complex — is essential for developing targeted therapies and for genetic counselling of couples with recurrent pregnancy loss.

4. The Menstrual Cycle

4.1 Phases of the Ovarian Cycle

The ovarian cycle is divided into the follicular phase, ovulation, and the luteal phase. During the follicular phase, a cohort of antral follicles grows under FSH stimulation; granulosa cells proliferate and acquire LH receptors, while theca cells produce androgens that are aromatised to estradiol. Rising estradiol exerts negative feedback on FSH, leading to atresia of all but the dominant follicle, which continues to secrete increasing amounts of estradiol. The sustained high estradiol level switches the feedback to positive, triggering the mid‑cycle LH surge that induces resumption of meiosis I, follicular rupture, and release of the secondary oocyte. After ovulation, the remnants of the follicle luteinise under LH influence, forming the corpus luteum that secretes progesterone and estradiol during the luteal phase, which lasts about 14 days in a typical 28‑day cycle.

4.2 Phases of the Uterine Cycle

The uterine (endometrial) cycle mirrors the ovarian cycle but is described in three phases: menstrual, proliferative, and secretory. Menstruation marks the shedding of the functional layer of the endometrium when progesterone and estradiol fall after corpus luteum regression. The proliferative phase coincides with the follicular phase; estrogen stimulates rapid regeneration of the endometrial glands, stroma, and spiral arteries, restoring the functional layer to a thickness of several millimetres. Following ovulation, the secretory phase is driven by progesterone, which induces glandular secretion of glycogen‑rich fluid, stromal edema, and coiling of spiral arteries, creating a nutrient‑rich, immunologically modulated environment for potential implantation. If implantation does not occur, the corpus luteum degenerates, hormone support withdraws, and the cycle restarts with menstruation.

4.3 Hormonal Interplay and Feedback Loops

The menstrual cycle exemplifies a tightly regulated endocrine feedback system. Early follicular FSH rise is permitted by low estradiol and inhibin B levels; as the dominant follicle matures, estradiol rises sharply, first suppressing FSH (negative feedback) and then, once a threshold is crossed, sensitising the pituitary to GnRH, producing the LH surge (positive feedback). After ovulation, the corpus luteum secretes progesterone, which together with estradiol exerts strong negative feedback on both GnRH and gonadotropins, preventing a second LH surge. Inhibin A, produced by the luteal granulosa cells, selectively suppresses FSH during the luteal phase. The decline of progesterone and estradiol at the end of the luteal phase removes this inhibition, allowing FSH to rise again and initiate the next follicular wave. This cyclical pattern is essential for the selection of a single dominant follicle and for the temporal coordination of ovarian and uterine events.

Major hormone concentrations across the menstrual cycle phases
PhaseFollicle‑stimulating hormone (FSH)Luteinising hormone (LH)EstradiolProgesterone
Early follicularModerate riseLowLowLow
Late follicular (pre‑ovulatory)DecliningSurgePeakLow
LutealLowLowModerateHigh
MenstruationRisingLowLowLow

4.4 Cycle Length Variations and Disorders

While a 28‑day cycle is often cited as typical, normal menstrual cycles range from 21 to 35 days, with the follicular phase showing the greatest variability and the luteal phase remaining relatively constant at 12 to 14 days. Polycystic ovary syndrome (PCOS) is characterised by chronic anovulation, hyperandrogenism, and polycystic ovarian morphology; the lack of a regular LH surge leads to prolonged follicular phases and irregular bleeding. Hypothalamic amenorrhoea results from suppressed GnRH pulsatility due to stress, low body weight, or excessive exercise, producing low gonadotropins and estrogen deficiency. Luteal phase defect, where progesterone production is insufficient to maintain the secretory endometrium, can cause infertility or early pregnancy loss. Understanding these variations is crucial for diagnosing menstrual disorders and for timing interventions such as ovulation induction or endometrial preparation in assisted reproduction.

5. Fertilisation, Implantation and Early Embryonic Development

5.1 Fertilisation in the Ampulla

Fertilisation typically occurs in the ampullary region of the fallopian tube, where the oocyte, surrounded by the cumulus oophorus and zona pellucida, encounters capacitated spermatozoa. Capacitation, a series of membrane and metabolic changes acquired during transit through the female tract, enables sperm to undergo the acrosome reaction upon binding to ZP3 glycoproteins of the zona pellucida. The acrosome reaction releases hydrolytic enzymes that allow a single sperm to penetrate the zona and fuse with the oolemma. Fusion triggers the cortical reaction, in which cortical granules release their contents into the perivitelline space, modifying the zona pellucida to block polyspermy. The sperm nucleus decondenses to form the male pronucleus, while the oocyte completes meiosis II, forming the female pronucleus and the second polar body; the two pronuclei then migrate toward each other, their nuclear envelopes break down, and the first mitotic spindle forms, establishing the diploid zygote.

5.2 Cleavage and Blastocyst Formation

The zygote undergoes a series of rapid mitotic divisions called cleavage, during which the overall embryo size remains constrained within the zona pellucida. Early cleavage divisions are meridional and produce blastomeres that are initially totipotent; by the 8‑cell stage, compaction occurs, maximising cell‑cell contact and establishing polarity. Subsequent divisions generate a morula of 16‑32 cells, which then cavitates as fluid accumulates in the central cavity, forming the blastocyst. The blastocyst consists of an outer trophoblast layer that will give rise to the placenta and an inner cell mass (ICM) that will form the embryo proper. The ICM differentiates into the epiblast and hypoblast, establishing the bilaminar disc. Throughout cleavage, the embryo relies on maternal mRNAs and proteins stored in the oocyte; zygotic genome activation occurs around the 4‑ to 8‑cell stage in humans, marking the transition to embryonic control of development.

5.3 Implantation and Placental Beginnings

Around day 5 to 6 post‑fertilisation, the blastocyst reaches the uterine cavity and hatches from the zona pellucida, a process facilitated by proteases secreted by the trophoblast. The trophoblast differentiates into an outer syncytiotrophoblast, which erodes the endometrial epithelium and invades the stromal tissue, and an inner cytotrophoblast that retains proliferative capacity. The syncytiotrophoblast secretes human chorionic gonadotropin (hCG), which rescues the corpus luteum, ensuring continued progesterone production that maintains the decidua. By day 12, the conceptus is fully embedded in the endometrium, and lacunae within the syncytiotrophoblast fill with maternal blood, establishing the uteroplacental circulation. The chorionic villi, formed by cytotrophoblast cores covered by syncytiotrophoblast, become the functional units of nutrient and gas exchange. Successful implantation requires a receptive endometrium — the “window of implantation” — characterised by specific integrin expression, cytokine milieu, and immune modulation; failure at any step leads to early pregnancy loss.

6. Reproductive Health and Assisted Technologies

6.1 Contraceptive Methods and Their Mechanisms

Contraception aims to prevent fertilisation or implantation through hormonal, barrier, intrauterine, surgical, or behavioural means. Combined oral contraceptives contain estrogen and progestin, suppressing the LH surge and thus ovulation, while also thickening cervical mucus and thinning the endometrium. Progestin‑only pills, injectables, and implants primarily act by thickening cervical mucus and altering endometrial receptivity, with variable ovulation suppression. Copper‑bearing intrauterine devices (IUDs) release copper ions that are toxic to sperm and ova and provoke a sterile inflammatory response that impairs implantation. Hormonal IUDs release levonorgestrel locally, producing similar mucus and endometrial effects with minimal systemic exposure. Barrier methods such as condoms, diaphragms, and cervical caps physically block sperm entry and also reduce transmission of sexually transmitted infections. Surgical sterilisation — vasectomy in males and tubal ligation in females — provides permanent occlusion of the gamete transport pathways. Emergency contraception, using high‑dose progestin or a copper IUD, can prevent pregnancy after unprotected intercourse by delaying ovulation or preventing implantation if used within the appropriate time window.

Hormonal Regulation of Implantation and Early Pregnancy Maintenance

Successful implantation depends on a precisely timed endocrine dialogue between the conceptus and the maternal endometrium. After fertilisation, the developing blastocyst begins secreting human chorionic gonadotropin (hCG) as early as day 6 post‑fertilisation. hCG binds to luteinising hormone/choriogonadotropin receptors on the corpus luteum, preventing its luteolysis and sustaining progesterone and estradiol production. Progesterone induces the secretory transformation of the endometrium, up‑regulating integrins (αvβ3, α4β1), glycodelin, and leukemia inhibitory factor (LIF) that create the “window of implantation” — a 4‑day period (approximately days 20‑24 of a 28‑day cycle) when the endometrium is receptive. Estradiol synergises with progesterone to promote stromal decidualisation, a process in which endometrial stromal cells differentiate into decidual cells that secrete prolactin, insulin‑like growth factor binding protein‑1 (IGFBP‑1), and cytokines such as interleukin‑11 (IL‑11). These factors modulate local immune cells, especially uterine natural killer (uNK) cells, shifting them toward a tolerant phenotype that supports trophoblast invasion without rejecting the semi‑allogeneic conceptus.

By the end of the second week, the syncytiotrophoblast produces sufficient hCG to maintain the corpus luteum until the luteal‑placental shift at approximately 8‑10 weeks gestation, when the placenta assumes steroidogenesis. During this transition, placental trophoblasts express the enzyme 3β‑hydroxysteroid dehydrogenase, converting pregnenolone to progesterone, while the fetal zone of the adrenal cortex supplies dehydroepiandrosterone sulfate (DHEA‑S) for placental estrogen synthesis. The rising estrogen/progesterone ratio further remodels the spiral arteries, establishing the low‑resistance uteroplacental circulation essential for nutrient and gas exchange. Disruption at any stage — inadequate hCG, luteal phase defect, impaired decidualisation, or abnormal uNK cell function — can lead to implantation failure, early pregnancy loss, or later placental insufficiency manifesting as pre‑eclampsia or intrauterine growth restriction.

Clinical assessment of this axis includes serum hCG kinetics (doubling time ~48 h in early viable pregnancy), progesterone levels (>10 ng/mL generally considered supportive), and endometrial biopsy dating (though rarely used now). In assisted reproduction, exogenous progesterone supplementation (vaginal micronised progesterone 400‑800 mg daily or intramuscular 50‑100 mg) is standard from the day of oocyte retrieval until placental autonomy is confirmed by ultrasound at 7‑8 weeks. Emerging research explores the role of endometrial receptivity arrays (ERA) that transcriptomically define the personalised window of implantation, allowing tailored embryo transfer timing.

Assisted Reproductive Technologies: IVF, ICSI, Preimplantation Genetic Testing, and Cryopreservation

In vitro fertilisation (IVF) begins with controlled ovarian stimulation (COS) using gonadotropins (recombinant FSH, hMG) combined with a GnRH agonist or antagonist to prevent premature LH surge. Monitoring by serial transvaginal ultrasound and estradiol levels guides trigger timing; a final maturation trigger (hCG 5,000‑10,000 IU or GnRH agonist 0.2 mg) is administered when ≥3 follicles reach ≥17 mm. Oocyte retrieval is performed 34‑36 h later under ultrasound guidance. Retrieved cumulus‑oocyte complexes are either inseminated conventionally (≈50,000‑100,000 motile sperm per oocyte) or subjected to intracytoplasmic sperm injection (ICSI) where a single immobilised sperm is injected directly into the ooplasm. ICSI is indicated for severe male factor infertility (oligo‑astheno‑teratozoospermia), previous fertilisation failure, or when using surgically retrieved sperm (TESE, PESA).

Fertilisation is assessed 16‑18 h post‑insemination by the presence of two pronuclei (2PN). Zygotes are cultured in sequential media mimicking the tubal and uterine environment; by day 3 they typically reach the 6‑8 cell stage, and by day 5‑6 they form blastocysts with a distinct inner cell mass (ICM) and trophectoderm. Blastocyst transfer (single embryo transfer is increasingly recommended to reduce multiple pregnancy) yields higher implantation rates per embryo than cleavage‑stage transfer. Preimplantation genetic testing (PGT) can be performed on trophectoderm biopsies (5‑10 cells) at the blastocyst stage. PGT‑A (aneuploidy screening) uses next‑generation sequencing to select euploid embryos, improving live‑birth rates especially in advanced maternal age. PGT‑M (monogenic disorders) and PGT‑SR (structural rearrangements) target specific inherited mutations or chromosomal translocations.

Cryopreservation by vitrification (ultra‑rapid cooling with high‑concentration cryoprotectants) has replaced slow‑freezing for both oocytes and embryos, achieving >90 % survival and comparable clinical outcomes to fresh cycles. Oocyte vitrification enables fertility preservation for oncology patients, elective age‑related banking, and donor oocyte programmes. Embryo vitrification facilitates “freeze‑all” strategies to avoid ovarian hyperstimulation syndrome (OHSS) and to allow endometrial preparation in a subsequent natural or hormone‑replacement cycle. Cumulative live‑birth rates per COS cycle now exceed 60 % in many centres when fresh and frozen transfers are combined. Complications include OHSS (graded mild to severe), multiple gestation (mitigated by elective single embryo transfer), and a modest increase in preterm birth and low birth weight with frozen‑thawed cycles, possibly related to altered endometrial‑embryo synchrony.

Examiner's trap: Cumulative live‑birth calculation
A 32‑year‑old woman undergoes one COS cycle yielding 8 mature oocytes. After ICSI, 6 embryos reach blastocyst stage. Two euploid blastocysts are identified by PGT‑A. The clinic reports a 55 % implantation rate per euploid blastocyst transferred. If she transfers one euploid blastocyst in a fresh cycle and the remaining one in a subsequent frozen‑thawed cycle, what is the approximate cumulative probability of at least one live birth assuming independence and a 10 % miscarriage rate after implantation?
Step 1: Probability of implantation per transfer = 0.55. Step 2: Probability of live birth per implanted embryo = 1 – 0.10 = 0.90. Step 3: Probability of live birth per transfer = 0.55 × 0.90 = 0.495. Step 4: Probability of no live birth after two independent transfers = (1 – 0.495)² = 0.505² ≈ 0.255. Step 5: Cumulative probability of at least one live birth = 1 – 0.255 = 0.745, i.e., ≈74.5 %.
Exam‑day strategy
When a question asks for cumulative success across multiple ART cycles, always convert each step (implantation, clinical pregnancy, live birth) into a single per‑transfer probability, then apply the complement rule (1 – product of failure probabilities). Write the intermediate probabilities clearly; examiners award partial marks for correct method even if arithmetic slips.

Common Endocrine Disorders Affecting Fertility: Polycystic Ovary Syndrome, Endometriosis, Premature Ovarian Insufficiency, and Male Hypogonadism

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine cause of anovulatory infertility, affecting 8‑13 % of reproductive‑age women depending on diagnostic criteria. The Rotterdam criteria require two of three features: oligo‑/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology (≥12 follicles 2‑9 mm per ovary or ovarian volume >10 mL). Insulin resistance and compensatory hyperinsulinaemia amplify ovarian theca cell androgen production and reduce hepatic sex hormone‑binding globulin, worsening free androgen excess. First‑line ovulation induction uses letrozole (aromatase inhibitor) 2.5‑7.5 mg daily for 5 days, which yields higher live‑birth rates and lower multiple pregnancy risk than clomiphene citrate. Metformin (1.5‑2 g/day) improves insulin sensitivity and can restore ovulation, especially in women with impaired glucose tolerance. For clomiphene‑/letrozole‑resistant PCOS, gonadotropin therapy with low‑dose step‑up protocols or laparoscopic ovarian drilling (electrocautery of 4‑10 cortical punctures) are options before proceeding to IVF.

Endometriosis, defined by ectopic endometrial‑like tissue, affects 10‑15 % of women and up to 30‑50 % of infertile women. The disease creates a chronic inflammatory peritoneal environment with elevated prostaglandins, cytokines (TNF‑α, IL‑1, IL‑6), and oxidative stress that impair oocyte quality, sperm function, tubal motility, and endometrial receptivity. Staging (rASRM I‑IV) correlates poorly with fertility potential; deep infiltrating endometriosis and endometriomas >3 cm are associated with reduced ovarian reserve (lower AMH, fewer antral follicles). Surgical excision of endometriomas improves spontaneous pregnancy rates but may further diminish reserve; therefore, IVF is often preferred for stages III‑IV, especially when tubal factor co‑exists. GnRH agonist down‑regulation for 3‑6 months before IVF can improve outcomes in advanced disease.

Premature ovarian insufficiency (POI) — cessation of ovarian function before age 40 — occurs in ~1 % of women. Aetiologies include chromosomal abnormalities (Turner syndrome mosaicism, FMR1 premutation), autoimmune oophoritis, iatrogenic (chemotherapy, radiotherapy), and idiopathic. Diagnosis requires ≥4 months of amenorrhoea with two FSH levels >25 IU/L in the follicular phase. Hormone replacement therapy (HRT) with estradiol 2 mg oral or 100 µg transdermal plus cyclic progestogen is indicated for bone, cardiovascular, and vasomotor health until the average age of natural menopause. Fertility options are limited to oocyte donation, as spontaneous conception rates are <5 %.

Male hypogonadism contributing to infertility can be primary (testicular failure: Klinefelter syndrome 47,XXY, Y‑chromosome microdeletions, post‑orchitis, varicocele) or secondary (hypothalamic‑pituitary dysfunction: Kallmann syndrome, hyperprolactinaemia, exogenous testosterone suppression). Evaluation includes serum testosterone, LH, FSH, prolactin, and semen analysis. Varicocele repair (microsurgical subinguinal) improves semen parameters in ~60‑70 % and natural pregnancy rates in ~30‑40 % of couples. For hypogonadotropic hypogonadism, pulsatile GnRH or combined hCG/FSH therapy restores spermatogenesis over 6‑12 months. In non‑obstructive azoospermia, micro‑TESE retrieves sperm in 40‑60 % of cases for ICSI. Genetic counselling is mandatory for Klinefelter and Y‑microdeletion carriers due to transmission risk.

Contraceptive Effectiveness, Failure Mechanisms, and Emerging Male Contraceptive Strategies

Contraceptive efficacy is expressed as the Pearl Index (pregnancies per 100 woman‑years) under perfect use and typical use. Combined oral contraceptives (COCs) have a perfect‑use Pearl Index of 0.3 but typical‑use index of 7‑9 due to missed pills, drug interactions (enzyme inducers such as rifampicin, certain anticonvulsants), and gastrointestinal malabsorption. Progestin‑only pills (POPs) require strict 3‑hour dosing window; typical‑use failure rises to 9‑11. Copper IUDs (Cu‑T380A) show perfect‑use 0.6 and typical‑use 0.8, with failure mainly from expulsion (2‑5 % in first year) or uterine perforation (0.1 %). Levonorgestrel IUDs (LNG‑IUS 52 mg) have typical‑use 0.2, failure often due to expulsion or displacement. Male condoms exhibit typical‑use 13‑18, driven by breakage, slippage, and inconsistent use. Female sterilisation (tubal ligation) failure is 0.5‑1.0 over 10 years, mainly from recanalisation or fistula formation. Vasectomy failure (recanalisation) is 0.1‑0.2 % after confirmed azoospermia.

Emergency contraception (EC) with levonorgestrel 1.5 mg (within 72 h) or ulipristal acetate 30 mg (within 120 h) primarily delays ovulation; copper IUD inserted ≤5 days post‑coitus is the most effective EC (failure <0.1 %). Failure of EC occurs when ovulation has already occurred (LH surge initiated) or when implantation has begun; ulipristal retains efficacy closer to the LH surge due to progesterone receptor modulation.

Male contraceptive development targets either hormonal suppression of spermatogenesis or non‑hormonal disruption of sperm function. Hormonal regimens combine a long‑acting androgen (testosterone undecanoate 1000 mg IM every 12 weeks or transdermal gel) with a progestin (norethisterone enanthate, depot medroxyprogesterone acetate) to suppress gonadotropins to <1 IU/L, achieving azoospermia or severe oligozoospermia (<1 million/mL) in >90 % of men within 6‑12 months. Phase III trials (e.g., NCT02841886) demonstrated a Pearl Index of 1.5 with acceptable safety, but mood changes, libido reduction, and injection site reactions limited acceptability. Non‑hormonal approaches include reversible inhibition of sperm under guidance (RISUG) — a styrene maleic anhydride polymer injected into the vas deferens that disrupts sperm membrane integrity; Phase III data from India show >99 % contraceptive efficacy over 3 years with reversibility demonstrated by dimethyl sulfoxide flush. Another target is the epididymal protein CRISP1 or the sperm‑specific calcium channel CatSper; small‑molecule inhibitors are in pre‑clinical stages. A male oral pill targeting the retinoic acid receptor‑α (RAR‑α) antagonist (e.g., YCT529) has entered first‑in‑human trials. Regulatory approval will require demonstration of rapid reversibility, minimal metabolic impact, and long‑term safety.

Legal and Ethical Frameworks Governing Assisted Reproduction and Pregnancy Termination

National legislation defines the permissible scope of assisted reproductive technologies (ART) and pregnancy termination. The Medical Termination of Pregnancy (MTP) Act, 1971, amended in 2003 and 2021, allows termination up to 24 weeks gestation for specific indications (risk to life, grave physical/mental health injury, fetal anomalies, contraceptive failure in married women, and rape). Beyond 24 weeks, a medical board must certify substantial fetal abnormality incompatible with life. The Act mandates provider certification, facility registration, and consent requirements (guardian consent for minors, spousal consent not legally required). The Surrogacy (Regulation) Act, 2021 permits only altruistic surrogacy for Indian heterosexual married couples with proven infertility, prohibits commercial surrogacy, and establishes a National Surrogacy Board. The Assisted Reproductive Technology (Regulation) Act, 2021 mandates registration of ART clinics and banks, sets standards for gamete donation (age 21‑35 for oocyte donors, 21‑55 for sperm donors), limits the number of donations per donor, and requires pre‑implantation genetic testing only for known hereditary conditions. Embryo research is restricted to embryos ≤14 days or primitive streak formation, consistent with the international “14‑day rule”.

Ethical guidelines from the Indian Council of Medical Research (ICMR) and the National Academy of Medical Sciences address informed consent, confidentiality, and the welfare of the future child. Donor anonymity is preserved in gamete donation, but offspring may access non‑identifying medical information at age 18. Preimplantation genetic diagnosis (PGD) for sex selection is prohibited; PGD for monogenic diseases is permitted with appropriate counselling. Embryo cryopreservation storage limits are set at 10 years, extendable with couple consent. Cross‑border reproductive care raises jurisdictional conflicts; clinics must comply with both the country of treatment and the patients’ home country regulations. Emerging issues include mitochondrial replacement therapy (MRT) for mitochondrial disease prevention — currently not permitted in India — and genome editing of human embryos, which remains prohibited globally for clinical use.

Healthcare providers must document indication, gestational age, counselling, and consent meticulously to withstand legal scrutiny. Failure to adhere to statutory timelines (e.g., MTP beyond permitted weeks without board approval) constitutes a criminal offence. Similarly, offering commercial surrogacy or facilitating sex‑selective ART attracts penal provisions. Continuous medical education on evolving legislation is essential for clinicians to maintain compliant practice.

  • Assuming hCG alone maintains the corpus luteum indefinitely — the luteal‑placental shift at 8‑10 weeks is essential for sustained progesterone.
  • Confusing PGT‑A (aneuploidy screening) with PGT‑M (monogenic disease) — they use different probe designs and counselling pathways.
  • Treating PCOS‑related anovulation with clomiphene as first line despite evidence favouring letrozole for higher live‑birth rates.
  • Equating typical‑use Pearl Index with perfect‑use values when comparing contraceptive methods — typical use reflects real‑world adherence.
  • Believing male hormonal contraception achieves instant azoospermia — spermatogenesis suppression requires 3‑6 months.
  • Overlooking the 14‑day rule for embryo research — any culture beyond primitive streak formation is prohibited.
  • Assuming donor anonymity is absolute — many jurisdictions now allow offspring access to identifying information at adulthood.

These advanced topics integrate endocrine physiology, laboratory technique, clinical decision‑making, and regulatory knowledge required for high‑stakes examinations.

Implantation Window and Endometrial Receptivity Markers

The implantation window is a narrow temporal interval, typically days 20‑24 of a 28‑day menstrual cycle, during which the endometrium acquires a receptive phenotype capable of accepting a competent blastocyst. This receptivity is orchestrated by a precise sequence of steroid hormone actions: estrogen primes the epithelium during the proliferative phase, while progesterone, rising after ovulation, drives secretory transformation and induces the expression of adhesion molecules, cytokines, and transcription factors that define the receptive state.

Key molecular markers include the integrin αvβ3, which appears on the apical surface of luminal epithelial cells around day 20 and serves as a ligand for osteopontin on the trophoblast. Leukemia inhibitory factor (LIF) peaks in the mid‑secretory phase and is essential for blastocyst attachment; LIF‑null mice fail to implant. Homeobox A10 (HOXA10) and HOXA11 are transcription factors whose expression is progesterone‑dependent and whose loss leads to implantation failure. Pinopodes, apical membrane protrusions visible by scanning electron microscopy between days 20‑22, correlate with maximal receptivity and are used as a morphological hallmark.

Clinical translation of these markers has produced the Endometrial Receptivity Array (ERA), a transcriptomic assay that classifies endometrial biopsies as receptive, pre‑receptive, or post‑receptive. The test guides personalized embryo transfer (pET) timing, especially in recurrent implantation failure (RIF) cohorts. Meta‑analyses report modest improvements in live‑birth rates when pET is applied to RIF patients, but routine use in unselected IVF cycles remains controversial due to cost and limited incremental benefit.

Disorders that shift the window include luteal phase deficiency, where insufficient progesterone shortens the receptive interval, and endometriosis, which alters the expression of integrins, LIF, and HOXA10. Polycystic ovary syndrome (PCOS) is associated with advanced endometrial maturation relative to embryonic development, a phenomenon termed “endometrial advancement.” Therapeutic strategies such as progesterone supplementation, GnRH agonist trigger, or freeze‑all cycles aim to synchronize embryonic and endometrial chronology.

Emerging research explores microRNA signatures (e.g., miR‑30d, miR‑30b) and metabolomic profiles of uterine fluid as non‑invasive receptivity biomarkers. While promising, these assays have not yet reached clinical validation thresholds comparable to ERA.

Maternal‑Fetal Immunological Tolerance Mechanisms

Successful pregnancy requires the maternal immune system to tolerate a semi‑allogeneic fetus expressing paternal antigens. The trophoblast, which lacks classical HLA‑A, ‑B, and ‑DR expression, instead presents the non‑classical HLA‑G, HLA‑E, and HLA‑F molecules. HLA‑G binds inhibitory receptors (ILT2, ILT4, KIR2DL4) on uterine natural killer (uNK) cells, dendritic cells, and macrophages, dampening cytotoxic responses and promoting angiogenic cytokine secretion (VEGF, PlGF).

Uterine NK cells constitute ~70 % of decidual leukocytes in early pregnancy. Unlike peripheral NK cells, they are poorly cytotoxic and produce growth factors that facilitate spiral artery remodeling. Their education is governed by the interaction between fetal HLA‑C (the only polymorphic classical HLA expressed by extravillous trophoblast) and maternal killer‑cell immunoglobulin‑like receptors (KIR). Specific KIR/HLA‑C combinations (e.g., KIR AA genotype with fetal HLA‑C2) are associated with increased risk of pre‑eclampsia and fetal growth restriction.

Regulatory T cells (Tregs) expand systemically and locally during pregnancy, driven by fetal antigen presentation and the cytokine milieu (TGF‑β, IL‑10). Tregs suppress Th1/Th17 effector responses and promote tolerance through CTLA‑4‑mediated dendritic cell modulation and secretion of IL‑35. Depletion of Tregs in murine models leads to fetal resorption, underscoring their non‑redundant role.

Indoleamine 2,3‑dioxygenase (IDO) expressed by trophoblast and dendritic cells catabolizes tryptophan, creating a local immunosuppressive microenvironment. The PD‑1/PD‑L1 pathway further restrains T‑cell activation at the maternal‑fetal interface. Disruption of these pathways — by infection, autoimmune disease, or genetic polymorphisms — can precipitate recurrent pregnancy loss or placental insufficiency.

Clinical correlates include the observation that women with antiphospholipid syndrome exhibit reduced HLA‑G expression and skewed uNK phenotypes. Immunomodulatory therapies (low‑dose aspirin, heparin, intravenous immunoglobulin) aim to restore tolerance but remain evidence‑based only for defined indications.

Examiner's trap
A 32‑year‑old woman with two consecutive first‑trimester miscarriages is found to have a KIR AA genotype and her partner is HLA‑C2 homozygous. Which immunological mechanism best explains the increased miscarriage risk?
The KIR AA genotype lacks activating KIR receptors; when fetal trophoblast expresses HLA‑C2, the inhibitory KIR2DL1 on maternal uNK cells engages HLA‑C2 without counter‑balancing activating signals. This results in insufficient uNK‑derived angiogenic factors, impaired spiral artery remodeling, and placental insufficiency, manifesting as early pregnancy loss.
Exam‑day strategy
Memorise the three non‑classical HLA molecules (G, E, F) and their primary receptors (ILT2/4, NKG2A/CD94, KIR2DL4). Pair each with its functional outcome (inhibition of cytotoxicity, angiogenesis, trophoblast invasion). This triad appears repeatedly in multiple‑choice questions on implantation immunology.

Epigenetic Reprogramming in Early Embryo and Assisted Reproduction

After fertilisation, the paternal genome undergoes active DNA demethylation mediated by TET3‑oxidation of 5‑methylcytosine to 5‑hydroxymethylcytosine, while the maternal genome is passively demethylated through successive cleavage divisions. By the blastocyst stage, global methylation reaches a nadir, after which de novo methylation by DNMT3A/3B establishes lineage‑specific patterns. Imprinted loci escape this wave, retaining parental‑specific methylation marks established during gametogenesis.

Assisted reproductive technologies (ART) — ovarian stimulation, in vitro culture, embryo biopsy, and cryopreservation — can perturb these epigenetic dynamics. Superovulation alters the follicular milieu, affecting oocyte cytoplasmic factors (e.g., Stella, DPPA3) that protect maternal imprints. Culture media composition (serum vs. defined, oxygen tension) influences the timing of zygotic genome activation and the fidelity of imprint maintenance. Studies in mice show that serum‑containing media increase the incidence of loss of imprinting at the H19/Igf2 locus.

Human epidemiological data link ART to a modestly elevated risk of imprinting disorders, notably Beckwith‑Wiedemann syndrome (BWS; loss of methylation at KCNQ1OT1) and Silver‑Russell syndrome (SRS; hypomethylation at H19/IGF2). The absolute risk remains low (≈1‑4 per 10 000 ART births) but is significantly higher than in spontaneous conceptions. Preimplantation genetic testing for aneuploidy (PGT‑A) involves trophectoderm biopsy at the blastocyst stage; while generally safe, the removal of 5‑10 cells may transiently affect epigenetic regulation, though long‑term data are reassuring.

Emerging strategies to mitigate epigenetic risk include the use of sequential, serum‑free media with defined amino acid and antioxidant profiles, reduced oxygen (5 %) culture, and minimising embryo manipulation time. Epigenetic biomarkers such as methylation levels at differentially methylated regions (DMRs) in spent culture medium are under investigation as non‑invasive predictors of imprinting integrity.

Clinicians should counsel couples that the baseline risk of imprinting disorders is low, that ART‑associated risk is relative, and that current evidence does not support routine epigenetic screening of embryos.

Ovarian Reserve Assessment: Biomarkers and Clinical Algorithms

Ovarian reserve reflects the quantity and quality of the remaining follicular pool and predicts response to controlled ovarian stimulation (COS). The most widely used biomarkers are anti‑Müllerian hormone (AMH), antral follicle count (AFC) by transvaginal ultrasound, basal follicle‑stimulating hormone (FSH) on cycle day 2‑3, and inhibin B. AMH, produced by granulosa cells of pre‑antral and small antral follicles, correlates strongly with AFC and declines steadily with age, becoming undetectable ≈5 years before menopause.

AMH assays have evolved from manual ELISA to automated platforms (e.g., Beckman Coulter Access, Roche Elecsys). Inter‑assay variability has been reduced by the introduction of an international standard (NIBSC 90/672), yet clinicians must be aware of platform‑specific reference ranges. AFC, counted as follicles 2‑10 mm in both ovaries, provides a direct visual estimate; a total AFC < 5 indicates diminished reserve, while AFC > 15 suggests hyper‑response risk.

Clinical algorithms integrate these markers with patient age and body mass index (BMI). The Bologna criteria (2011) define poor ovarian response (POR) as ≥2 of: (1) age ≥ 40 years or other risk factor, (2) previous POR (≤3 oocytes), (3) abnormal ovarian reserve test (AMH < 1.1 ng/mL or AFC < 5). The POSEIDON classification (2016) stratifies patients into four groups based on age (<35 vs ≥35), ovarian reserve (AMH/AFC), and prior response, guiding individualized stimulation protocols.

Dynamic tests such as the clomiphene citrate challenge test (CCCT) and the exogenous FSH ovarian reserve test (EFORT) have largely been superseded by AMH/AFC due to lower invasiveness and comparable predictive value. However, basal FSH remains useful when AMH is borderline, as an elevated FSH (>10 IU/L) with normal AMH may signal early follicular phase dysregulation.

Interpretation pitfalls include the effect of oral contraceptive pills (OCPs) which suppress AMH by 20‑30 % and AFC by ~15 %; measurements should be performed after a washout period of ≥4 weeks. Vitamin D deficiency, obesity, and smoking also modestly lower AMH. Conversely, AMH can be falsely elevated in polycystic ovary syndrome (PCOS) due to increased granulosa cell mass, necessitating combined assessment with AFC.

Male Infertility Genetics: Y Chromosome Microdeletions and CFTR Mutations

The azoospermia factor (AZF) region on the long arm of the Y chromosome (Yq11.23) is subdivided into AZFa, AZFb, and AZFc. Microdeletions in these intervals are the most frequent known genetic cause of severe oligozoospermia and non‑obstructive azoospermia (NOA), detected in 5‑10 % of NOA and 2‑5 % of severe oligozoospermia cases. AZFa deletions (encompassing USP9Y, DBY) are associated with Sertoli‑cell‑only syndrome; AZFb deletions (RBMY, PRY) cause meiotic arrest; AZFc deletions (DAZ, CDY, BPY2) show variable phenotypes, sometimes permitting sperm retrieval by testicular sperm extraction (TESE).

Current guidelines (European Academy of Andrology, American Society for Reproductive Medicine) recommend AZF screening for all men with sperm concentration <5 million/mL before intracytoplasmic sperm injection (ICSI). Testing uses multiplex PCR targeting sequence‑tagged sites (STS) across the three AZF subregions. Complete AZFa or AZFb deletions predict near‑zero chance of sperm retrieval; AZFc deletions have a 50‑70 % retrieval rate. Men with AZFc deletions transmit the deletion to all male offspring, mandating genetic counselling.

Cystic fibrosis transmembrane conductance regulator (CFTR) mutations underlie congenital bilateral absence of the vas deferens (CBAVD), presenting as obstructive azoospermia with normal testicular histology and low semen volume, acidic pH, and absent fructose. Over 2 000 CFTR variants exist; the classic ΔF508 allele accounts for ~70 % of alleles in Caucasian populations, but rare variants (5T/7T/9T polythymidine tract in intron 9) modify penetrance. Men with CBAVD should undergo comprehensive CFTR sequencing (including intron 9 poly‑T analysis) and partner testing to assess offspring risk of cystic fibrosis.

Other monogenic causes include mutations in SYCP3 (meiotic arrest), NR5A1 (SF1) (mixed gonadal dysgenesis), and DNA repair genes (e.g., MLH1, MSH4) linked to meiotic failure. Whole‑exome sequencing is entering diagnostic pipelines for idiopathic NOA, but clinical utility remains limited to research settings.

Clinical workflow: (1) semen analysis confirming azoospermia/oligozoospermia; (2) hormonal profile (FSH, LH, testosterone, inhibin B); (3) scrotal ultrasound to exclude obstruction; (4) karyotype and AZF microdeletion PCR; (5) if CBAVD suspected, CFTR sequencing; (6) genetic counselling and discussion of ICSI with testicular sperm. This algorithm maximises the chance of biological parenthood while informing reproductive risk.

  • Assuming AMH alone defines ovarian reserve — AFC and age must be integrated for accurate stratification.
  • Equating AZFc deletion with guaranteed sperm retrieval — retrieval rates are only 50‑70 % and vary by laboratory expertise.
  • Overlooking the need for partner CFTR testing in CBAVD — offspring risk of cystic fibrosis depends on both parental alleles.
  • Treating ERA as a universal solution for all IVF cycles — evidence supports use mainly in recurrent implantation failure.
  • Believing HLA‑G expression alone ensures tolerance — coordinated uNK education, Treg expansion, and IDO activity are all required.
  • Ignoring the effect of OCPs on AMH — measurements during OCP use underestimate true reserve.
  • Assuming imprinting disorders are common after ART — absolute risk remains low; counselling should reflect population‑level data.
The advanced sections above integrate molecular mechanisms, clinical algorithms, and genetic counselling points essential for high‑stakes examinations.

Practice Questions

← Nervous System, Endocrine & Locomotion Principles of Inheritance & Molecular Basis →